DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks

Information source: Boston University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Induced Abortion; Abortion Techniques; Mifepristone; Misoprostol

Intervention: Mifepristone (Drug); Misoprostol (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Boston University

Official(s) and/or principal investigator(s):
Primary Investigator, Principal Investigator, Affiliation: Boston University

Overall contact:
Principal Investigator, Phone: 617-414-7310, Email: fpresearch@bmc.org

Summary

Surgical abortion in the late first trimester and early second trimester is usually performed with the aid of a cervical preparing agent, which helps to open up the uterine cervix for the procedure. Routine use of cervical preparants is recommended by several organizations during this period of pregnancy before surgical abortion, especially in younger women or those who have not delivered a baby, because their cervices may be more difficult to dilate without a preparant. The standard medication used for cervical preparation is misoprostol. Unfortunately, misoprostol may cause uncomfortable uterine cramping and vaginal bleeding in patients who use it. Another medication called mifepristone has been shown to dilate the cervix better than misoprostol in the first trimester, but little information exists about using mifepristone in the late first trimester and early second trimester. The investigators plan to perform a prospective, double-blind, randomized trial to evaluate if mifepristone is a better cervical preparant than misoprostol. A total of 110 participants who are pregnant women desiring pregnancy termination 11 to 15 weeks gestational age will be recruited. Half will receive mifepristone and the other half misoprostol. The investigators will measure the amount of cervical dilation achieved right before a surgical abortion to determine if mifepristone is significantly different than misoprostol as a cervical preparant at this stage of pregnancy. The investigators expect that mifepristone will work better than misoprostol for this purpose. The investigators hope to generate information about mifepristone so that women and their health care providers can know more about mifepristone as an option for cervical preparation before surgical abortion.

Clinical Details

Official title: Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Initial cervical dilation at the time of surgical abortion

Secondary outcome:

Additional cervical dilation required to complete abortion procedure

Time to conduct procedure

Percentage of patients who report nausea, vomiting, diarrhea, and vaginal bleeding

Preoperative, intraoperative, and postoperative pain score

Surgeon's difficulty rating of procedure

Complications of procedure

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Age greater or equal to 18 years

- Fluency in English or Spanish

- Intrauterine pregnancy between 11 0/7 and 15 0/7 on the day of the abortion procedure

- Desire for pregnancy termination

- Ability to return for abortion procedure 24-48 hours after the preoperative visit

Exclusion Criteria:

- Allergy or contraindication to study agents

- Requirement of general anesthesia to perform the abortion

- Diagnosis of missed abortion, spontaneous abortion, incomplete abortion, or

threatened abortion at time of initial preoperative evaluation

Locations and Contacts

Principal Investigator, Phone: 617-414-7310, Email: fpresearch@bmc.org

Boston University Medical Center, Boston, Massachusetts 02118, United States; Recruiting
Primary Investigator, Phone: 617-414-7310, Email: fpresearch@bmc.org
Primary Investigator, Principal Investigator
Additional Information

Starting date: June 2012
Last updated: July 5, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017